Evidence-Based Medical News

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine Orthopedics & Sports Medicine OB/GYN & Women's Health Radiology & Imaging Genetics & Precision Medicine Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Urology Ophthalmology Dermatology Emergency Medicine Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

letrozole

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of letrozole

91 trials tracked of letrozole: 29 in phase 3 or 4 and 16 with published results. The most-cited published study has 723 citations.

91Trials tracked

29Phase 3 & 4

0Recruiting

16With published results

Phase distribution

Phase 4 7 Phase 3 22 Phase 2 47 Phase 1 5 Other / NA 10

Phase 3 Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer Completed · 723 cited
Phase 3 Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy Completed · 650 cited
Phase 3 Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer Completed · 562 cited
Phase 3 Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Completed · 269 cited
Phase 3 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Completed · 225 cited
Phase 3 A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2) Completed · 178 cited

Show 44 more trials

Phase 3 Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women Completed · 133 cited
Phase 3 Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer Completed · 129 cited
Phase 3 Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer Completed · 122 cited
Phase 4 Combined Letrozole and Clomid in Women With Infertility and PCOS Completed · 97 cited
Phase 3 A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4] Completed · 78 cited
Phase 3 Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer Completed · 37 cited
Phase 3 Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC Completed · 35 cited
Phase 4 Aromatase Inhibitor Growth Study: Letrozole vs. Anastrozole Completed · 30 cited
Phase 3 Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia Completed · 10 cited
Phase 3 Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate Completed · 4 cited
Phase 4 Pilot of Letrozole for Uterine Myomas Completed
Phase 4 RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF Completed
Phase 4 Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer Completed
Phase 4 Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer Completed
Phase 4 The Role of Estrogen in Luteinizing Hormone Surge and Ovulation Completed
Phase 3 Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer Completed
Phase 3 The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer Completed
Phase 3 Pregnancy in Polycystic Ovary Syndrome II Completed
Phase 3 Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer. Completed
Phase 3 Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer Completed
Phase 3 Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy Completed
Phase 3 Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer Completed
Phase 3 A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer Completed
Phase 2 TRial on the Endocrine Activity of Neoadjuvant Degarelix Completed
Phase 2 Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Completed
Phase 2 Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer Completed
Phase 2 Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer Completed
Phase 2 Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms Completed
Phase 2 Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ Completed
Phase 2 Letrozole in Preventing Breast Cancer in Postmenopausal Women Completed
Phase 2 Effect of Aromatase Inhibitors on Breast Magnetic Resonance Imaging (MRI) Completed
Phase 2 Protocol for Women at Increased Risk of Developing Breast Cancer Completed
Phase 2 BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer Completed
Phase 2 A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer Completed
Phase 2 Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis Completed
Phase 2 Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer Completed
Phase 2 Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer Completed
Phase 2 Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer Completed
Phase 2 Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments Completed
Phase 2 Letrozole for Lymphangioleiomyomatosis Completed
Phase 2 Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer Completed
Phase 2 A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer Completed
Phase 2 Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer Completed
Phase 2 Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ Completed

Showing the 50 most-cited and recently-updated of 91 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.